“Our intent is to grow much faster than the market. Patent are expiries are important events coming up. We are working strategically and also watching the vildagliptin patent expiry and how the various strategies employed by companies
are working in the market,” said Sharad Tyagi, managing director of Boehringer Ingelheim India.
When a drug goes off patent, the market usually expands as more doctors start prescribing the drug as prices become competitive. By the time linagliptin patent expires, vildagliptin and sitagliptin (two diabetes drugs) would have lost their patents and the market would become really big, Tyagi said. “We need to see what are the price elasticity and the scientific benefits we still have. The brands develop and create loyalty among the stakeholders, be it the physicians or the patients,” he said.
It is focused on just 10 brands in India, of which five are in diabetes, two are in oncology, and the rest are in pulmonary (lung disease) and cardiac and stroke prevention and management.
“We are not growing the number of brands from a branded generic perspective. We are clear that we will focus on our innovative pipeline,” he said, adding that over the next three to four years Boehringer would focus on consolidating the base from its current position.